|
|
Career Enhancement Program |
| 5P50CA136393-12 |
|
NCI |
2022 |
|
|
Career Enhancement Program (CEP) |
| 5P50CA171963-10 |
|
NCI |
2022 |
|
|
Developmental Research Program |
| 5P50CA210964-05 |
|
NCI |
2022 |
|
|
Career Enhancement Program |
| 5P50CA228991-05 |
|
NCI |
2022 |
|
|
Very-long Term Neurocognitive Outcomes in Breast Cancer Survivors |
| 5R01CA172145-08 |
|
NCI |
2022 |
|
|
Preventing Falls and Frailty in Prostate Cancer Survivors: GET FIT Prostate |
| 5R01CA222605-05 |
|
NCI |
2022 |
|
|
Predicting Long-Term Chemotherapy-Related Cognitive Impairment |
| 5R01CA226080-04 |
|
NCI |
2022 |
|
|
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study |
| 5R01CA235726-05 |
|
NCI |
2022 |
|
|
A Mobile Health Behavioral Pain Intervention Protocol for Breast Cancer Patients with Pain in Medically Underserved Communities: A Randomized Controlled Trial |
| 5R01CA237892-03 |
|
NCI |
2022 |
|
|
MRI study of chemobrain in pediatric oncology patients |
| 5R01CA244768-03 |
|
NCI |
2022 |
